A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
Clinical trial NCT01871805 · COMPLETED
Trial details
- NCT number
- NCT01871805
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-09-30
- Primary completion
- 2014-10-24
- Enrollment
- 134
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.